DB05754ExperimentalSmall molecule
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ...
- Mechanism
- Curator reviewed
Pharmacologically active on T cell receptor delta variable 2 and T cell receptor gamma variable 9
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C), leukemia (myeloid), and lymphoma (non-hodgkin's).Curator reviewed
- Code names
- IPH 1101
Resolves to
Compound
Targets
What you can answer from here — as of July 03, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with IPH 1101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account